Sai Life Sciences Limited

Sai Life Sciences Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L24110TG1999PLC030970 Incorporated 25 January 1999 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed Public Limited Company pharma
Data last updated
Market Cap
₹33,879 Cr
SAILIFE · NSE
Share Price
₹1,592.20
-0.17% today
Revenue
₹2,192 Cr
FY 2025-26 · +21.8% YoY
EBITDA
₹625 Cr
Margin 28.5%
Net Profit
₹356 Cr
FY 2025-26 · +107.4% YoY
P/E (TTM)
93.0x
P/B 13.8x
ROE
15.1%
ROCE 19.1%
Debt / Equity
0.14
Interest cover 8.9x

About Sai Life Sciences Limited

Data last updated: 27 September 2026

Sai Life Sciences Limited is a public limited company based in Hyderabad, Telangana, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 25 January 1999, the company has been in operation for over 27 years.

Registered with ROC Hyderabad under CIN L24110TG1999PLC030970. Listed.

Capital: an authorised share capital of ₹25 Cr and a paid-up capital of ₹21.23 Cr. Formerly known as Sai Dru Syn Laboratories Limited and Sai Advantium Pharma Limited Definitions & Interpretation. It is led by directors including Krishnamraju Kanumuri and Sivaramakrishnan Chittor.

Last AGM: 11 September 2025. Financial statements filed for year ended 31 March 2025. Office: 7 Ikp Knowledge Park, Hyderabad, Telangana.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,192.49 Cr, a growth of 29.38% compared to the previous year. The net worth stands at ₹2,483.69 Cr (up 16.7% YoY). Total assets are valued at ₹2,804.46 Cr (up 11.99% YoY).

The company has a workforce of approximately 2,995 employees as per the latest available data.

The company is associated with 1 brand - Sai Life Sciences. As per MCA filings, the company has open charges of ₹962.36 Cr and satisfied charges of ₹1,590.09 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sailife.com.

Company Details of Sai Life Sciences Limited
CIN L24110TG1999PLC030970
Registration Number 030970
Incorporation Date 25 January 1999
ROC Hyderabad
Listing Status Listed
Company Status Active
Date of Last AGM 11 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Krishnamraju Kanumuri Managing Director Sivaramakrishnan Chittor Whole-Time Director Ranga Raju Kanumuri Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    Locked
  • Social Media
  • Registered Address
    Plot No. Ds – 7 Ikp Knowledge Park Turkapally (V) Shameerpet Mandal Medchal – Malkajgiri Di, St, Hyderabad, Telangana, India – 500078
  • Industry
    Pharma, API Manufacturers, Pharma Contract R&D
Company report
Sai Life Sciences Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Sai Life Sciences Limited report

Financials, compliance, directors, charges, ownership and filings for Sai Life Sciences Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Sai Life Sciences Limited

Sai Life Sciences Limited has undergone 4 name changes throughout its history. The current legal name is Sai Life Sciences Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Sai Life Sciences Limited Current
Sai Dru Syn Laboratories Limited Previous
Sai Advantium Pharma Limited Definitions & Interpretation Previous
Sai Life Sciences Limited Definitions & Interpretation Previous
Sai Advantium Pharma Limited Previous

CIN History of Sai Life Sciences Limited

Sai Life Sciences Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24110TG1999PLC030970, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24110TG1999PLC030970 Current
U24110TG1999PLC030970 Previous
U24110AP1999PLC030970 Previous

Associated Brands with Sai Life Sciences Limited

Sai Life Sciences Limited operates one associated brand: Sai Life Sciences. These brands represent Sai Life Sciences Limited's diversified market presence and brand portfolio.

Brand Description Website
Sai Life Sciences
Complex small molecules are discovered, developed, and manufactured for pharmaceuticals. sailife.com

Competitors & Alternatives of Sai Life Sciences Limited

Brands and companies operating in the same space as Sai Life Sciences Limited include Acies Bio, Liverpool ChiroChem, IRBM and 5 more.

Competitor Description Location Founded
Acies Bio Acies Bio Provider of drug discovery and development services to pharmaceutical, biotech, and food industries Ljubljana, Slovenia, Slovenia 2006
Liverpool ChiroChem Liverpool ChiroChem Small organic molecules are supplied for biotech and pharmaceutical R&D. Liverpool, United Kingdom, United Kingdom 2014
IRBM IRBM Integrated drug discovery and preclinical development services are provided. Pomezia, Italy, Italy 2010
New Iridium New Iridium Phenoxazine and dihydrophenazine are manufactured by New Iridium. Boulder, United States, United States 2016
NFIL NFIL Fluorinated compounds are synthesized and manufactured customly for various industries. Mumbai, India, India 1967
Personal Chemistry Personal Chemistry Coherent Synthesis is developed for medicinal and combinatorial chemistry applications. Uppsala, Sweden, Sweden 1998
Automera Automera Autophagy-driven degradation is pioneered through computational chemistry and AI. Singapore, Singapore, Singapore 2022
SpiroChem SpiroChem Swiss fine chemicals company providing API, Intermediates and custom synthesis services for the pharma and biotech industry Zurich, Switzerland, Switzerland 2011

Business Activity of Sai Life Sciences Limited

Sai Life Sciences Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
M Professional, Scientific and Technical M5 Scientific research and development Locked
Premium access

Business activity turnover details for Sai Life Sciences Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Board of Directors of Sai Life Sciences Limited

Sai Life Sciences Limited is currently managed by 6 directors, with 28 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Krishnamraju Kanumuri
Also directs: Sai Life Sciences Limited, Sai Life Pharma Private Limited, South India Research Institute Pvt Ltd
Managing Director 01 Oct 2010 15 Years 11 Months Current
Sivaramakrishnan Chittor
Also directs: Sai Life Sciences Limited
Whole-Time Director 28 Apr 2025 1 Years 4 Months Current
Ranga Raju Kanumuri
Also directs: Jrv Properties Llp, Sai Life Sciences Limited, Sai Quest Syn Private Limited and 3 more
Whole-Time Director 25 Jan 1999 27 Years 8 Months Current
Suchita Sharma
Also directs: Sai Life Sciences Limited, Roppen Transportation Services Private Limited
Director 10 Jun 2024 2 Years 3 Months Current
Ramesh Ganesh Iyer
Also directs: Sai Life Sciences Limited, Kotak Mahindra Bank Limited, Nocil Limited and 4 more
Director 21 May 2024 2 Years 4 Months Current
Dinesh V Patel
Also directs: Sai Life Sciences Limited
Director 24 Mar 2025 1 Years 6 Months Current
View all directors

Financials of Sai Life Sciences Limited FY 2025-26 filings available

Sai Life Sciences Limited reported revenue of ₹2,192.49 Cr (up 29.38% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,192 Cr
+29.4% YoY
EBITDA
₹625 Cr
+53.2% YoY
Profit After Tax
₹356 Cr
+107.4% YoY
Net Worth
₹2,484 Cr
+16.7% YoY
Total Assets
₹2,804 Cr
+12.0% YoY
Total Debt
₹288 Cr
-18.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1921,6951,4651,217870760726
Revenue growth+21.8%+9.2%+12.4%+41.0%+25.5%+6.2%+7.4%
EBITDA625408287169126167168
EBITDA margin+28.5%+24.1%+19.6%+13.9%+14.5%+22.0%+23.1%
Profit before tax46622810916.419.7081.91109
Net profit35617182.7810.21(5.08)61.0976.34
Net profit margin+16.2%+10.1%+5.7%+0.8%-0.6%+8.0%+10.5%
EPS (₹)16.488.1646.895.673.5535.0646.59
Balance sheet
Total assets2,8042,5041,9241,8411,8411,5481,145
Net worth2,4842,128975888879863794
Total debt288352928932751637304
Cash & bank11146415986.3413076.4198.25
Net working capital670960680681685595390
Cash flow
Cash from operations509314263219105(36.38)116
Cash from investing(395)(536)(191)(99.00)(102)(260)(262)
Cash from financing(124)301(95.30)(201)71.92296(4.07)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue554602556537496580440396
Revenue growth (YoY)+11.7%+3.9%+26.5%+35.9%+77.5%+31.9%+14.6%+9997.0%
Other income3.5415.818.3815.339.909.609.129.95
EBITDA148177180146121158120102
EBITDA margin+26.7%+29.3%+32.3%+27.1%+24.4%+27.2%+27.2%+25.8%
Depreciation45.9445.3144.0839.7537.7237.4934.0935.92
Interest7.647.839.709.3512.3610.8923.1320.93
Profit before tax97.9713913411280.7511971.6555.32
Tax24.6934.9933.8028.2020.3030.5317.8013.82
Net profit73.2810410083.8560.4588.2753.8541.50
EPS (₹)3.424.874.713.932.904.142.842.21
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1531,6421,4191,157841751725
Revenue growth+24.8%+10.5%+14.1%+38.3%+21.9%+5.7%+6.7%
EBITDA593392288167125164170
EBITDA margin+27.6%+23.9%+20.3%+14.4%+14.9%+21.9%+23.4%
Profit before tax45623212932.6822.3687.59114
Net profit34817595.2224.614.3865.3180.13
Net profit margin+16.2%+10.7%+6.7%+2.1%+0.5%+8.7%+11.1%
EPS (₹)16.128.3253.9213.768.9336.6548.92
Balance sheet
Total assets2,7632,4781,8991,8021,7901,5451,137
Net worth2,5082,1671,011913891868794
Total debt223287868869751637304
Cash & bank10845815280.0212470.1092.97
Net working capital641947697684690584401
Cash flow
Cash from operations49533025122188.38(25.94)109
Cash from investing(393)(565)(190)(111)(94.63)(279)(259)
Cash from financing(109)314(84.63)(190)80.95304(1.40)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue547594549527483567429382
Revenue growth (YoY)+13.2%+4.8%+28.1%+37.9%+82.6%+32.6%+15.0%+9997.0%
Other income3.5416.048.4514.9310.019.829.459.95
Total expenses407426378387370413317281
EBITDA140168171140113154111101
EBITDA margin+25.6%+28.3%+31.1%+26.6%+23.4%+27.1%+25.9%+26.4%
Depreciation42.1341.1640.6036.2134.3334.1031.0732.78
Interest5.986.168.067.7010.709.1621.6619.45
Profit before tax95.3313713011177.9812067.9158.48
Tax23.9934.3232.8427.9219.6230.5316.8514.64

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 27 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue554602556537496580440396
Revenue growth (YoY)+11.7%+3.9%+26.5%+35.9%+77.5%+31.9%+14.6%+9997.0%
Other income3.5415.818.3815.339.909.609.129.95
EBITDA148177180146121158120102
EBITDA margin+26.7%+29.3%+32.3%+27.1%+24.4%+27.2%+27.2%+25.8%
Depreciation45.9445.3144.0839.7537.7237.4934.0935.92
Interest7.647.839.709.3512.3610.8923.1320.93
Profit before tax97.9713913411280.7511971.6555.32
Tax24.6934.9933.8028.2020.3030.5317.8013.82
Net profit73.2810410083.8560.4588.2753.8541.50
EPS (₹)3.424.874.713.932.904.142.842.21
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1921,6951,4651,217870760726
Revenue growth+21.8%+9.2%+12.4%+41.0%+25.5%+6.2%+7.4%
Other income49.1336.7829.0927.9728.1527.2917.84
Total expenses1,5681,2871,1781,048743593558
Employee cost683549495417301232214
EBITDA625408287169126167168
EBITDA margin+28.5%+24.1%+19.6%+13.9%+14.5%+22.0%+23.1%
Depreciation16713911999.4390.1679.5754.70
Interest40.8878.3487.5681.0254.4833.1421.70
Profit before tax46622810916.419.7081.91109
Tax11757.5726.436.423.4720.8232.76
Net profit35617182.7810.21(5.08)61.0976.34
Net profit margin+16.2%+10.1%+5.7%+0.8%-0.6%+8.0%+10.5%
EPS (₹)16.488.1646.895.673.5535.0646.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital21.1820.8418.0518.0117.9417.8216.38
Reserves & surplus2,4632,107957870861845777
Shareholders' funds (net worth)2,4842,128975888879863794
Minority interest0.000.000.000.000.000.000.00
Secured loans95.13129710699718603291
Unsecured loans19322421823333.8033.9812.42
Total debt288352928932751637304
Total liabilities2,8042,5041,9241,8411,8411,5481,145
Assets
Gross block2,6072,1161,6791,418937859810
Net block1,8151,4881,1801,037751701641
Capital work in progress27012410715141024690.96
Investments50.501.941.871.870.020.020.02
Inventories15111987.4414012776.3544.04
Sundry debtors374355256284243206270
Cash & bank balances11146415986.3413076.4198.25
Loans & advances728567443454444445201
Total current assets1,3641,505945964944804613
Total current liabilities693545265283259208222
Net working capital670960680681685595390
Total assets2,8042,5041,9241,8411,8411,5481,145
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash91.0511.9735.5311640.6241.40192
Net cash from operating activities509314263219105(36.38)116
Net cash from investing activities(395)(536)(191)(99.00)(102)(260)(262)
Net cash from financing activities(124)301(95.30)(201)71.92296(4.07)
Net change in cash(9.14)79.08(23.56)(80.25)75.15(0.78)(150)
Closing cash11146415986.3413076.4198.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+29.4%+15.7%+20.4%+40.0%+14.4%+4.7%+4.4%
EBITDA growth+53.2%+42.0%+70.0%+33.8%-24.6%-0.2%-4.5%
PBT growth+104.7%+108.5%+565.6%+69.2%-88.2%-24.9%-3.5%
Net income growth+107.4%+107.1%+710.8%+9998.0%--20.0%+3.9%
Revenue CAGR (3Y)+21.7%+24.9%+24.5%+18.8%+7.8%--
EBITDA CAGR (3Y)+54.7%+47.9%+19.7%+0.2%-10.4%--
Profitability & leverage
Net income margin+15.9%+10.0%+5.7%+0.8%+0.7%+8.0%+10.5%
Return on capital employed+19.1%+13.8%+10.5%+5.3%+3.1%+8.6%+12.1%
Return on net worth+15.1%+11.0%+8.9%+1.1%-0.6%+7.4%+10.1%
Debt / equity0.140.411.000.950.800.570.37
Long-term debt / equity0.070.200.490.430.310.200.10
Interest cover8.9329.1052.22116.64151.2137.7619.21
Efficiency & per share
Fixed asset turnover0.930.890.951.030.970.911.12
Inventory turnover16.2516.4312.919.148.5612.6216.40
Debtors turnover6.025.555.424.623.883.202.88
EPS (₹)16.488.1646.895.673.5535.0646.59
Dividend per share (₹)0.000.000.0038.3339.630.000.00
Book value per share (₹)117.28102.12551.96503.80500.21494.88484.03
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue547594549527483567429382
Revenue growth (YoY)+13.2%+4.8%+28.1%+37.9%+82.6%+32.6%+15.0%+9997.0%
Other income3.5416.048.4514.9310.019.829.459.95
Total expenses407426378387370413317281
EBITDA140168171140113154111101
EBITDA margin+25.6%+28.3%+31.1%+26.6%+23.4%+27.1%+25.9%+26.4%
Depreciation42.1341.1640.6036.2134.3334.1031.0732.78
Interest5.986.168.067.7010.709.1621.6619.45
Profit before tax95.3313713011177.9812067.9158.48
Tax23.9934.3232.8427.9219.6230.5316.8514.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1531,6421,4191,157841751725
Revenue growth+24.8%+10.5%+14.1%+38.3%+21.9%+5.7%+6.7%
Other income49.1337.3429.3327.9628.1527.2917.84
Total expenses1,5601,2501,131991716587556
Employee cost618486431354263204202
EBITDA593392288167125164170
EBITDA margin+27.6%+23.9%+20.3%+14.4%+14.9%+21.9%+23.4%
Depreciation15212610787.7779.7071.7752.36
Interest34.0871.9481.1574.3850.9832.1121.26
Profit before tax45623212932.6822.3687.59114
Tax11558.2633.788.456.6722.2833.95
Net profit34817595.2224.614.3865.3180.13
Net profit margin+16.2%+10.7%+6.7%+2.1%+0.5%+8.7%+11.1%
EPS (₹)16.128.3253.9213.768.9336.6548.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital21.1820.8418.0518.0117.9417.8216.38
Reserves & surplus2,4872,147993895873850777
Shareholders' funds (net worth)2,5082,1671,011913891868794
Secured loans95.13129710699718603291
Unsecured loans12815915717033.8033.9812.42
Total debt223287868869751637304
Total liabilities2,7632,4781,8991,8021,7901,5451,137
Assets
Gross block2,4131,9441,5261,270884815784
Net block1,7051,3781,074923701659617
Capital work in progress27012410715134523678.97
Investments16311480.2780.2763.5663.3622.38
Inventories15011886.0713812673.3342.93
Sundry debtors370353259277237203269
Cash & bank balances10845815280.0212470.1092.97
Loans & advances725565454457457446204
Total current assets1,3521,495951952944792609
Total current liabilities711548254268253208208
Net working capital641947697684690584401
Total assets2,7632,4781,8991,8021,7901,5451,137
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash85.125.1729.2110934.3136.12188
Net cash from operating activities49533025122188.38(25.94)109
Net cash from investing activities(393)(565)(190)(111)(94.63)(279)(259)
Net cash from financing activities(109)314(84.63)(190)80.95304(1.40)
Net change in cash(6.52)79.95(24.04)(79.80)74.70(1.81)(152)
Closing cash10845815280.0212470.1092.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+31.1%+15.7%+22.6%+37.6%+11.9%+3.6%+4.4%
EBITDA growth+51.3%+36.2%+72.6%+33.6%-23.9%-3.3%-2.8%
PBT growth+96.9%+79.6%+294.8%+46.2%-74.5%-23.2%+1.6%
Net income growth+99.2%+83.6%+286.9%+461.9%-93.3%-18.5%+10.0%
Revenue CAGR (3Y)+23.0%+25.0%+23.6%+16.9%+6.6%--
EBITDA CAGR (3Y)+52.6%+46.5%+20.6%-0.6%-10.6%--
Profitability & leverage
Net income margin+15.9%+10.6%+6.7%+2.1%+1.9%+8.7%+11.1%
Return on capital employed+18.7%+13.9%+11.4%+6.0%+3.7%+8.9%+12.6%
Return on net worth+14.6%+10.9%+9.9%+2.7%+0.5%+7.9%+10.6%
Debt / equity0.110.360.900.900.790.570.37
Long-term debt / equity0.040.160.410.390.310.180.09
Interest cover7.7327.0144.8894.03112.8134.7518.09
Efficiency & per share
Fixed asset turnover0.990.951.021.080.990.941.14
Inventory turnover16.0616.0712.668.778.4412.9316.61
Debtors turnover5.965.375.294.503.833.182.88
EPS (₹)16.128.3253.9213.768.9336.6548.92
Dividend per share (₹)0.000.000.0038.3339.630.000.00
Book value per share (₹)118.42104.00572.28517.79507.50486.92484.05
Want more history and ratios?
You're viewing the latest exchange-filed financials for Sai Life Sciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Charges & Borrowings of Sai Life Sciences Limited

Open charges
₹962.36 Cr
Satisfied charges
₹1,590.09 Cr
Breakdown by lending institutions
Sbicap Trustee Company Limited₹912.36 Cr
Axis Bank Limited₹50.00 Cr
Latest charge details
DateLenderAmountStatus
13 Mar 2026 Axis Bank Limited ₹50 Cr Open
06 Oct 2023 Sbicap Trustee Company Limited ₹768.6 Cr Open
06 Oct 2023 Sbicap Trustee Company Limited ₹25 Cr Open
06 Oct 2023 Sbicap Trustee Company Limited ₹18.76 Cr Open
06 Oct 2023 Sbicap Trustee Company Limited ₹100 Cr Open

Total charge records: 38 View all charges

Employees and EPFO Compliance at Sai Life Sciences Limited

View historical data on people associated with Sai Life Sciences Limited, including employment history and EPFO contributions.

Premium access

Employee and EPFO history for Sai Life Sciences Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Sai Life Sciences Limited

Premium access

GST registrations and filing compliance for Sai Life Sciences Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Sai Life Sciences Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Sai Life Sciences Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Sai Life Sciences Limited

Premium access

MSME payment history for Sai Life Sciences Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Sai Life Sciences Limited

Premium access

Corporate group structure for Sai Life Sciences Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Sai Life Sciences Limited

Premium access

MCA filings and documents for Sai Life Sciences Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Sai Life Sciences Limited

Charges
13 Mar 2026
A charge with Axis Bank Limited amounted to Rs. 50.00 Cr with Charge ID 101268280 was registered on 13 Mar 2026.
Activity
11 Sep 2025
Sai Life Sciences Limited last Annual general meeting of members was held on 11 Sep 2025 as per latest MCA records.
Directors
16 May 2025
Sivaramakrishnan Chittor was appointed as a Cfo on 16 May 2025 & has been associated with this company since 1 year 4 months.
Directors
28 Apr 2025
Sivaramakrishnan Chittor was appointed as a Whole-time director on 28 Apr 2025 & has been associated with this company since 1 year 5 months.
Activity
31 Mar 2025
Sai Life Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Charges
26 Mar 2025
A charge registered on 06 Oct 2023 via Charge ID 100817152 with Sbicap Trustee Company Limited was fully satisfied on 26 Mar 2025.

Recent News on Sai Life Sciences Limited

Investors flock to IPOs amid secondary market volatility
26 Jan 2025 · Thehindubusinessline

Frequently Asked Questions about Sai Life Sciences Limited

Sai Life Sciences Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 25 January 1999 (27+ years old) and is registered under CIN L24110TG1999PLC030970. The company has 2,995 employees.

Sai Life Sciences Limited reported revenue of ₹2,192.49 Cr for FY 2025-26 (up 29.38% YoY) based on consolidated financials.

The current directors of Sai Life Sciences Limited are:

The primary industry of Sai Life Sciences Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes, Sai Life Sciences Limited is a listed company.

Sai Life Sciences Limited can be reached at the registered office: Plot No. Ds – 7 Ikp Knowledge Park Turkapally V Shameerpet Mandal Medchal – Malkajgiri Di, St, Hyderabad, Telangana, India – 500078, or through the website sailife.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available